Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) today announced the company has initiated submission of a rolling New Drug Application (NDA) to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Management Comments

Alnylam Pharmaceuticals (ALNY) PT Lowered to $182 at Piper Jaffray; 'Cash of $1.9B to Launch Patisiran & Advance Pipeline'November 17, 2017 6:49 AM Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) AmyloidosisNovember 16, 2017 7:00 AM Blue Ridge 13F Shows New Stake in Ulta (ULTA), GNC (GNC), Increase in Visa (V) (More...)November 14, 2017 4:35 PM Alnylam Pharma (ALNY) Prices 5.6M Share Common Offering at $125/ShNovember 14, 2017 5:48 AM